Anti-Interleukin-9 Data Presented at the American Thoracic Society Meeting
24 Mai 2007 - 6:30PM
PR Newswire (US)
PLYMOUTH MEETING, Penn., May 24 /PRNewswire-FirstCall/ -- Genaera
Corporation (NASDAQ:GENR) today reported that MedImmune, Inc.
(NASDAQ:MEDI) presented data related to the Interleukin-9 (IL-9)
program at the American Thoracic Society (ATS) 2007 Annual
Conference held May 18-23 in San Francisco, California. Genaera and
MedImmune entered into a collaborative licensing agreement for this
program in 2001. MedImmune is conducting research to evaluate the
potential to use its fully humanized, developmental stage
monoclonal antibody (MAb) targeting IL-9 to treat or prevent
symptomatic, moderate-to-severe, persistent asthma. The ATS
presentations summarize several preclinical and clinical studies on
IL-9 biology and include results from two phase 1 clinical trials
to evaluate the safety and pharmacokinetics of the antibody, known
as MEDI-528, in healthy adults. IL-9 is associated with features of
asthma including increased airway inflammation, obstruction and
hyperresponsiveness, mucin production and mast cell generation.
Earlier preclinical study results have demonstrated that inhibition
of IL-9 leads to decreased airway inflammation and
hyperresponsiveness in animal models. The clinical results
presented at ATS indicate that the anti-IL-9 MAb, currently being
evaluated in a phase 2 trial in patients with asthma, was well
tolerated. "This first look at human anti-IL-9 data clearly
supports the clinical plan MedImmune has undertaken to advance this
novel potential treatment for patients with moderate to severe
asthma," said Jack Armstrong, President and Chief Executive Officer
of Genaera. "These data clearly support further study of MEDI-528
in asthma patients. We look forward to our continued relationship
with MedImmune and are pleased that the anti-IL-9 antibody is
progressing within their respiratory inflammation pipeline." In
addition to the clinical results described at ATS, results from
preclinical studies focused on the role of IL-9 in the pathology of
asthma were also presented. These data provide new insight into
IL-9's role in mast cell regulation and allergen-induced airway
remodeling. About Anti-IL-9 MAb IL-9 has been associated with
symptoms of asthma including mucous production, lung infiltration
of inflammatory cells, and IgE (an immune globulin associated with
allergic disease) production. It is one of at least 29 naturally
occurring interleukins in the human body. About Genaera Genaera
Corporation is focused on advancing the science and treatment of
metabolic diseases. We have significant market opportunities with a
first-in- class molecule that has the potential to redefine the
treatment paradigm for obesity and type 2 diabetes. In addition, we
have a value-driven, fully out- licensed partnership with MedImmune
for a second core program. Genaera is committed to directing
resources to its core program and the aggressive clinical
development of its key assets to build stockholder value. This
announcement contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are
subject to risks and uncertainties, known and unknown.
Forward-looking statements reflect management's current views and
are based on certain expectations and assumptions. Such statements
include, among others, statements regarding these preliminary
results, clinical development plans and prospects for Genaera's
programs including trodusquemine (MSI-1436), the IL-9 antibody
program, LOMUCIN(TM), or squalamine. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "believe," "continue," "develop," "expect,"
"plan" and "potential" or other words of similar meaning. Genaera's
actual results and performance could differ materially from those
currently anticipated and expressed in these and other
forward-looking statements as a result of a number of risk factors,
including, but not limited to: Genaera's history of operating
losses since inception and its need for additional funds to operate
its business; the costs, delays and uncertainties inherent in
scientific research, drug development, clinical trials and the
regulatory approval process; the risk that clinical trials for
Genaera's product candidates, including trodusquemine (MSI-1436),
the IL-9 antibody program, LOMUCIN(TM), or squalamine may be
delayed or may not be successful; the risk that Genaera may not
obtain regulatory approval for its products, whether due to
adequacy of the development program, the conduct of the clinical
trials, changing regulatory requirements, different methods of
evaluating and interpreting data, regulatory interpretations of
clinical risk and benefit, or otherwise; Genaera's reliance on its
collaborators, in connection with the development and
commercialization of Genaera's product candidates; market
acceptance of Genaera's products, if regulatory approval is
achieved; competition; general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical
industry; and the other risks and uncertainties discussed in this
announcement and in Genaera's filings with the U.S. Securities and
Exchange Commission, all of which are available from the Commission
in its EDGAR database at http://www.sec.gov/ as well as other
sources. You are encouraged to read these reports. Given the
uncertainties affecting development stage pharmaceutical companies,
you are cautioned not to place undue reliance on any such
forward-looking statements, any of which may turn out to be wrong
due to inaccurate assumptions, unknown risks, uncertainties or
other factors. Genaera does not intend (and it is not obligated) to
publicly update, revise or correct these forward-looking statements
or the risk factors that may relate thereto. DATASOURCE: Genaera
Corporation CONTACT: Investor Relations, Genaera Corporation,
+1-610-941-5675; or media, Susan Neath of Porter Novelli Life
Sciences, +1-619-849-6007, , for Genaera Corporation
Copyright
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
Von Dez 2023 bis Dez 2024